
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is making significant strides in its drug development and commercialization efforts with key deals in place with major healthcare providers, including a major National Coverage Agreement with UnitedHealthcare for coverage of CNSide and deals with Humana and Highmark. Additionally, they have made solid progress in their clinical trials and the launch of CNSide in 2026 is expected to be a major positive for the company's stock. The potential cost savings associated with CNSide for late-stage LM care also present a favorable outlook for the company's future. However, there are risks to attainment of the share price target, including potential failure of product candidates in clinical trials and regulatory approval.
Bears say
Plus Therapeutics is a clinical-stage pharmaceutical company with a negative outlook based on its risky balance sheet and the potential for future reverse splits, as well as the company's focus on clinical trials and commercial scale-up for their lead drug, REYOBIQ, which is currently being evaluated in a Phase 2 trial. Additionally, Plus Therapeutics has a high operating and net loss, which may be exacerbated by risks such as Clinical/Regulatory, Partnership and Financial, Commercial, Legal and Intellectual Property, and Market Share. While the company has received positive FDA feedback and has upcoming milestones, it may be prudent to take a wait-and-see approach until the stock and management demonstrate better execution.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares